The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy

References

• Jeong S, Park SH. Co-stimulatory receptors in cancers and their implications for cancer immunotherapy. Immune Netw. 2020;20(e3). doi:10.4110/in.2020.20.e3.
   Google Scholar
• Kwon BS, Weissman SM. cDNA sequences of two inducible T-cell genes. Proc Natl Acad Sci U S A. 1963-1967:86. doi:10.1073/pnas.86.6.1963.
   Google Scholar
• Hurtado JC, Kim SH, Pollok KE, Lee ZH, Kwon BS. Potential role of 4-1BB in T cell activation. Comparison with the costimulatory molecule CD28. J Immunol. 1995;155(7):3360–22. doi:10.4049/jimmunol.155.7.3360.
   PubMed Web of Science ®Google Scholar
• Pollok KE, Kim YJ, Zhou Z, Hurtado J, Kim KK, Pickard RT, Kwon BS. Inducible T cell antigen 4-1BB. Analysis of expression and function. J Immunol. 1993;150(3):771–81. doi:10.4049/jimmunol.150.3.771.
   PubMed Web of Science ®Google Scholar
• Vinay DS, Kwon BS. 4-1BB signaling beyond T cells. Cell Mol Immunol. 2011;8(281–284):281–84. doi:10.1038/cmi.2010.82.
   PubMedGoogle Scholar
• Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellström KE, Mittler RS, Chen L. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med. 1997;3(682–685):682–85. doi:10.1038/nm0697-682.
   PubMedGoogle Scholar
• Lee DY, Choi BK, Lee DG, Kim YH, Kim CH, Lee SJ, Kwon BS. 4-1BB signaling activates the t cell factor 1 effector/beta-catenin pathway with delayed kinetics via ERK signaling and delayed PI3K/AKT activation to promote the proliferation of CD8+ T Cells. PLoS One. 2013;8(e69677). doi:10.1371/journal.pone.0069677
   Google Scholar
• Wen T, Bukczynski J, Watts TH. 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function. J Immunol. 2002;168(4897–4906):4897–906. doi:10.4049/jimmunol.168.10.4897.
   PubMedGoogle Scholar
• Curran MA, Geiger TL, Montalvo W, Kim M, Reiner SL, Al-Shamkhani A, Sun JC, Allison JP. Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin. J Exp Med. 2013;210(743–755):743–55. doi:10.1084/jem.20121190.
   PubMedGoogle Scholar
• Song C, Sadashivaiah K, Furusawa A, Davila E, Tamada K, Banerjee A. Eomesodermin is required for antitumor immunity mediated by 4-1BB-agonist immunotherapy. Oncoimmunology. 2014;3(e27680):e27680. doi:10.4161/onci.27680.
   PubMedGoogle Scholar
• Willoughby JE, Kerr JP, Rogel A, Taraban VY, Buchan SL, Johnson PWM, Al-Shamkhani A. Differential impact of CD27 and 4-1BB costimulation on effector and memory CD8 T cell generation following peptide immunization. J Immunol. 2014;193(244–251):244–51. doi:10.4049/jimmunol.1301217.
   PubMedGoogle Scholar
• Sabbagh L, Pulle G, Liu Y, Tsitsikov EN, Watts TH. ERK-dependent Bim modulation downstream of the 4-1BB-TRAF1 signaling axis is a critical mediator of CD8 T cell survival in vivo. J Immunol. 2008;180(8093–8101):8093–101. doi:10.4049/jimmunol.180.12.8093.
   PubMedGoogle Scholar
• Woroniecka KI, Rhodin KE, Dechant C, Cui X, Chongsathidkiet P, Wilkinson D, Waibl-Polania J, Sanchez-Perez L, Fecci PE. 4-1BB agonism averts TIL exhaustion and licenses PD-1 blockade in glioblastoma and other intracranial cancers. Clin Cancer Res. 2020;26(1349–1358):1349–58. doi:10.1158/1078-0432.CCR-19-1068.
   PubMedGoogle Scholar
• Kim HD, Park S, Jeong S, Lee YJ, Lee H, Kim CG, Kim KH, Hong S-M, Lee J-Y, Kim S, et al. 4-1BB delineates distinct activation status of exhausted tumor-infiltrating CD8+T cells in hepatocellular carcinoma. Hepatology. 2020;71(955–971):955–71. doi:10.1002/hep.30881.
   PubMedGoogle Scholar
• Choi BK, Lee DY, Lee DG, Kim YH, Kim S-H, Oh HS, Han C, Kwon BS. 4-1BB signaling activates glucose and fatty acid metabolism to enhance CD8(+) T cell proliferation. Cell Mol Immunol. 2017;14(748–757):748–57. doi:10.1038/cmi.2016.02.
   PubMedGoogle Scholar
• Menk AV, Scharping NE, Rivadeneira DB, Calderon MJ, Watson MJ, Dunstane D, Watkins SC, Delgoffe GM. 4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses. J Exp Med. 2018;215(1091–1100):1091–100. doi:10.1084/jem.20171068.
   PubMedGoogle Scholar
• Ahmad A, Uddin S, Steinhoff M. CAR-T cell therapies: an overview of clinical studies supporting their approved use against acute lymphoblastic leukemia and large B-cell lymphomas. Int J Mol Sci. 2020;21(11):3906. doi:10.3390/ijms21113906.
   PubMed Web of Science ®Google Scholar
• Cilta-cel OK’d for Multiple Myeloma. Cancer Discov. 2022;12:1176. 10.1158/2159-8290.CD-NB2022-0019
   Google Scholar
• Cappell KM, Kochenderfer JN. A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains. Nat Rev Clin Oncol. 2021;18(715–727). doi:10.1038/s41571-021-00530-z.
   PubMedGoogle Scholar
• Hashimoto K. CD137 as an attractive T cell co-stimulatory target in the TNFRSF for immuno-oncology drug development. Cancers (Basel). 2021;13(10):2288. doi:10.3390/cancers13102288.
   PubMed Web of Science ®Google Scholar
• Skokos D, Waite JC, Haber L, Crawford A, Hermann A, Ullman E, Slim R, Godin S, Ajithdoss D, Ye, X, et al. A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies. Sci Transl Med. 2020;12(525). doi:10.1126/scitranslmed.aaw7888
   Web of Science ®Google Scholar
• Segal NH, Logan TF, Hodi FS, McDermott D, Melero I, Hamid O, Schmidt H, Robert C, Chiarion-Sileni V, Ascierto PA, et al. Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody. Clin Cancer Res. 2017;23(1929–1936):1929–36. doi:10.1158/1078-0432.CCR-16-1272.
   PubMedGoogle Scholar
• Chester C, Sanmamed MF, Wang J, Melero I. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies. Blood. 2018;131(49–57):49–57. doi:10.1182/blood-2017-06-741041.
   PubMedGoogle Scholar
• Chin SM, Kimberlin CR, Roe-Zurz Z, Zhang P, Xu A, Liao-Chan S, Sen D, Nager AR, Oakdale NS, Brown C, et al. Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab. Nat Commun. 2018;9(4679). doi:10.1038/s41467-018-07136-7
   Google Scholar
• Kamata-Sakurai M, Narita Y, Hori Y, Nemoto T, Uchikawa R, Honda M, Hironiwa N, Taniguchi K, Shida-Kawazoe M, Metsugi S, et al. Antibody to CD137 activated by extracellular adenosine triphosphate is tumor selective and broadly effective in vivo without systemic immune activation. Cancer Discov. 2021;11(158–175):158–75. doi:10.1158/2159-8290.CD-20-0328.
   PubMedGoogle Scholar
• Ho SK, Xu Z, Thakur A, Fox M, Tan SS, DiGiammarino E, Zhou L, Sho M, Cairns B, Zhao V, et al. Epitope and Fc-mediated cross-linking, but not high affinity, are critical for antitumor activity of CD137 agonist antibody with reduced liver toxicity. Mol Cancer Ther. 2020;19(1040–1051):1040–51. doi:10.1158/1535-7163.MCT-19-0608.
   PubMedGoogle Scholar
• Jhajj HS, Lwo TS, Yao EL, Tessier PM. Unlocking the potential of agonist antibodies for treating cancer using antibody engineering. Trends Mol Med. 2022. doi:10.1016/j.molmed.2022.09.012.
   PubMed Web of Science ®Google Scholar
• Liu X, Zhao Y, Shi H, Zhang Y, Yin X, Liu M, Zhang H, He Y, Lu B, Jin T, et al. Human immunoglobulin G hinge regulates agonistic anti-CD40 immunostimulatory and antitumour activities through biophysical flexibility. Nat Commun. 2019;10(4206). doi:10.1038/s41467-019-12097-6
   Google Scholar
• Orr CM, Fisher H, Yu X, Chan CHT, Gao Y, Duriez PJ, Booth SG, Elliott I, Inzhelevskaya T, Mockridge I, et al. Hinge disulfides in human IgG2 CD40 antibodies modulate receptor signaling by regulation of conformation and flexibility. Sci Immunol. 2022;7(eabm3723). doi:10.1126/sciimmunol.abm3723
   PubMedGoogle Scholar
• Li FB, Ravetch JV. Antitumor activities of agonistic anti-TNFR antibodies require differential Fc gamma RIIB coengagement in vivo. P Natl Acad Sci USA. 2013;110(19501–19506):19501–06. doi:10.1073/pnas.1319502110.
   PubMedGoogle Scholar
• Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5(520). doi:10.3389/fimmu.2014.00520.
   PubMedGoogle Scholar
• Claus C, Ferrara C, Wei X, Sam J, Lang S, Uhlenbrock F, Albrecht R, Herter S, Schlenker R, Hüsser T, et al. Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy. Sci Transl Med. 2019;11(496). doi:10.1126/scitranslmed.aav5989
   PubMed Web of Science ®Google Scholar
• Xu Y, Szalai AJ, Zhou T, Zinn KR, Chaudhuri TR, Li X, Koopman WJ, Kimberly RP. Fc gamma Rs modulate cytotoxicity of anti-Fas antibodies: implications for agonistic antibody-based therapeutics. J Immunol. 2003;171(562–568):562–68. doi:10.4049/jimmunol.171.2.562.
   PubMedGoogle Scholar
• Li Y, Tan S, Zhang C, Chai Y, He M, Zhang CW, Wang Q, Tong Z, Liu K, Lei Y, et al. Limited cross-Linking of 4-1BB by 4-1BB ligand and the agonist monoclonal antibody utomilumab. Cell Rep. 2018;25(4):909–920 e904. doi:10.1016/j.celrep.2018.09.073.
   PubMed Web of Science ®Google Scholar
• Eskiocak U, Guzman W, Wolf B, Cummings C, Milling L, Wu HJ, Ophir M, Lambden C, Bakhru P, Gilmore DC, et al. Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity. JCI Insight. 2020;5. doi:10.1172/jci.insight.133647.
   PubMed Web of Science ®Google Scholar
• Hinner MJ, Aiba RSB, Jaquin TJ, Berger S, Dürr MC, Schlosser C, Allersdorfer A, Wiedenmann A, Matschiner G, Schüler J, et al. Tumor-localized costimulatory T-cell engagement by the 4-1BB/HER2 bispecific antibody-anticalin fusion PRS-343. Clin Cancer Res. 2019;25(5878–5889):5878–89. doi:10.1158/1078-0432.CCR-18-3654.
   PubMedGoogle Scholar
• Su TT, Gao X, Wang J, Tumor-Localized A. Approach to bypass anti-4-1BB immuno-toxicity. Clin Cancer Res. 2019;25(5732–5734):5732–34. doi:10.1158/1078-0432.CCR-19-1799.
   PubMedGoogle Scholar
• Ku G, Bendell JC, Tolcher AW, Hurvitz SA, Krishnamurthy A, El-Khoueiry AB, Patnaik A, Shroff RT, Noonan A, Hahn NM, et al. A phase I dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies. Ann Oncol. 2020;31:S462–S463. doi:10.1016/j.annonc.2020.08.639.
   Web of Science ®Google Scholar
• Melero I, Sanmamed MF, Calvo E, Moreno I, Moreno V, Guerrero TCH, Martinez-Garcia M, Rodriguez-Vida A, Tabernero J, Pedrazzoli ABA, et al. First-in-human (FIH) phase I study of RO7122290 (RO), a novel FAP-targeted 4-1BB agonist, administered as single agent and in combination with atezolizumab (ATZ) to patients with advanced solid tumours. Ann Oncol. 2020;31:S707–S707. doi:10.1016/j.annonc.2020.08.1145.
   Web of Science ®Google Scholar
• Liu GZ, Du F, She XH, Zhu Y, Tolcher AW, Luo P. A safe and potent agonist ADG106 targeting a unique epitope of CD137 with novel mechanism of actions. Cancer Res. 2020;80. doi:10.1158/1538-7445.Am2020-4538.
   Web of Science ®Google Scholar
• Zhang L, Zhao HY, Ma YX, Zheng X, Jiang J, Zhang Y, Hong SD, Liu GZ, She XH, Ni QJ, et al. A phase I, dose-escalation study of ADG106, a fully human anti-CD137 agonistic antibody, in subjects with advanced solid tumors or relapsed/refractory non-Hodgkin lymphoma. J Clin Oncol. 2020;38(15_supplement): 3105.
   Web of Science ®Google Scholar
• Zhang L. Identification of a predictive biomarker and two pharmacodynamic biomarkers to ADG106 treatment, a novel anti-CD137 agonist antibody, in phase I clinical trials. J Clin Oncol. 2021:39. doi:10.1200/JCO.2021.39.15_suppl.e14505.
   Web of Science ®Google Scholar
• Elshiaty M, Schindler H, Christopoulos P. Principles and current clinical landscape of multispecific antibodies against cancer. Int J Mol Sci. 2021;22(11):5632. doi:10.3390/ijms22115632.
   PubMed Web of Science ®Google Scholar
• You G, Won J, Lee Y, Moon D, Park Y, Lee SH, Lee S-W. Bispecific antibodies: a smart arsenal for cancer immunotherapies. Vaccines (Basel). 2021;9(7). doi:10.3390/vaccines9070724.
   Web of Science ®Google Scholar
• Muik A, Garralda E, Altintas I, Gieseke F, Geva R, Ben-Ami E, Maurice-Dror C, Calvo E, LoRusso PM, Alonso G, et al. Preclinical characterization and Phase I trial results of a bispecific antibody targeting PD-L1 and 4-1BB (GEN1046) in patients with advanced refractory solid tumors. Cancer Discov. 2022;12(5):1248–65. doi:10.1158/2159-8290.CD-21-1345.
   PubMed Web of Science ®Google Scholar
• Geuijen C, Tacken P, Wang LC, Klooster R, van Loo PF, Zhou J, Mondal A, Liu JB, Kramer A, Condamine T, et al. A human CD137xPD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade. Nat Commun. 2021;12(4445). doi:10.1038/s41467-021-24767-5
   PubMedGoogle Scholar
• Prenen H, Kyi C, Van Lancker G, Patel SP, Mittag D, Weaver A, Bol K, Stalbovskaya V, Pulini J, Zhou G, et al. Phase I dose escalation study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1 in solid tumors. Ann Oncol. 2021;32:S1436–S1436. doi:10.1016/j.annonc.2021.10.155.
   Web of Science ®Google Scholar
• Link A, Juglair L, Poulet H, Lemaillet G, Reichen C, Schildknecht P, Tosevski I, Robinson J, Veitonmaki N, Herbst J, et al. Selection of first-in-human clinical dose range for the tumor-targeted 4-1BB agonist MP0310 (AMG 506) using a pharmacokinetic/pharmacodynamics modeling approach. Cancer Res. 2020;80(16_Supplement):2273–2273. doi:10.1002/1521-4141(2000012)30:12<3441::AID-IMMU3441>3.0.CO;2-L.
   PubMed Web of Science ®Google Scholar
• Tsun A, Zhai TH, Miao XN, Huang WF, Wang C, Xu YF, Yuan ZJ, Wang T, Dai S, Peng SG, et al. Discovery of a safer 4-1bb agonist by targeting a membrane-proximal epitope combined with bispecific-mediated cross-bridging. Journal for Immunotherapy of Cancer. 2021;9(Suppl 2):A939–A939. doi:10.1136/jitc-2021-SITC2021.895.
   Google Scholar
• Poh A. Dual Targeting Approach for CD40 and 4-1BB. Cancer Discov. 2022;12(1):9–10. doi:10.1158/2159-8290.Cd-Nb2021-0403.
   PubMed Web of Science ®Google Scholar
• Galand C, Venkatraman V, Marques M, Strauss J, Carvajal R, Lim M, Morin B, Ignatovich O, Findeis M, Underwood D, et al. AGEN2373 IS A CD137 agonist antibody designed to leverage optimal CD137 AND FC gamma R co-targeting to promote antitumor immunologic effects. J ImmunotherCancer. 2020;8:A229–A230. doi:10.1136/jitc-2020-SITC2020.0377.
   Web of Science ®Google Scholar
• Tolcher AW, Carvajal RD, El-Khoueiry AB, Ortuzar Feliu W, Zang H, Ancukiewicz M, Shapiro I, Strauss JF. Initial findings of the first-in-human phase I study of AGEN2373, a conditionally active CD137 agonist antibody, in patients (pts) with advanced solid tumors. J Clin Oncol. 2021;39(15_suppl):2634–2634. doi:10.1200/JCO.2021.39.15_suppl.2634.
   Web of Science ®Google Scholar
• Qi X, Li F, Wu Y, Cheng C, Han P, Wang J, Yang X. Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcgammaR affinity. Nat Commun. 2019;10(2141). doi:10.1038/s41467-019-10088-1.
   Google Scholar
• Fu SQ, Harb WA, Patel SP, Lu C, Halperin DM, Hsu YH, Shi N, Yamamura Y, Tang T, Jiang L, et al. Early safety and efficacy from a phase I open-label clinical trial of CD137(4-1BB) agonistic antibody LVGN6051 as monotherapy and in combination with pembrolizumab. J Clin Oncol. 2021;39(15_suppl):2521–2521. doi:10.1200/JCO.2021.39.15_suppl.2521.
   PubMed Web of Science ®Google Scholar
• Werchau D, Veitonmäki N, Hägerbrand K, Dahlman A, Smith KE, Fritzell S, von Schantz L, Thagesson M, Werchau D, Smedenfors K, et al. ATOR-1017, a 4-1BB antibody developed for tumor-directed immunotherapy of cancer. Journal for Immunotherapy of Cancer. 2019;7(1). doi:10.1186/s40425-019-0570-8.
   PubMedGoogle Scholar
• Dahlen E, Rosén A, Barchan K, Dahlman A, Ellmark P, Furebring T, Smith KE. ATOR-1017: a 4-1BB antibody designed for superior safety/efficacy profile in cancer immunotherapy. Cancer Immunol Res. 2019;7(2_Supplement):A183–A183. doi:10.1158/2326-6074.Cricimteatiaacr18-A183.
   PubMed Web of Science ®Google Scholar
• Ullenhag GJ, Yachnin J, Carneiro A, Elison E, Carlsson M, Russell CA, Enell Smith K. A first-in-human, multicenter, open-label, phase 1 study of ATOR-1017, a 4-1BB antibody, in patients with advanced solid malignancies. J Clin Oncol. 2021;39(15_suppl):2646–2646. doi:10.1200/JCO.2021.39.15_suppl.2646.
   Google Scholar
• Snell D, Gunde T, Warmuth S, Lichtlen P, Tietz J, Brock M, Simonin A, Hess C, Christopher W, Heiz R, et al. Preclinical development and mechanism of action studies of NM21-1480, a PD-L1/4-1BB/HSA trispecific MATCH3 therapeutic clinical candidate. Cancer Res. 2020;80(16_Supplement):2276–2276. doi:10.1158/1538-7445.Am2020-2276.
   Web of Science ®Google Scholar
• Warmuth S, Gunde T, Snell D, Brock M, Weinert C, Simonin A, Hess C, Tietz J, Johansson M, Spiga FM, et al. Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade. Oncoimmunology. 2021;10(1). Artn 2004661. doi:10.1080/2162402x.2021.2004661.
   PubMed Web of Science ®Google Scholar
• Cendrowicz E, Jacob L, Greenwald S, Tamir A, Pecker I, Tabakman R, Ghantous L, Tamir L, Kahn R, Avichzer J, et al. DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity. J Exp Clin Cancer Res. 2022;41(16_Supplement). doi:10.1158/1538-7445.AM2020-3352
   PubMedGoogle Scholar
• Gaspar M, Pravin J, Rodrigues L, Uhlenbroich S, Everett KL, Wollerton F, Morrow M, Tuna M, Brewis N. CD137/OX40 bispecific antibody induces potent antitumor activity that is dependent on target coengagement. Cancer Immunol Res. 2020;8(781–793):781–93. doi:10.1158/2326-6066.CIR-19-0798.
   PubMedGoogle Scholar
• Papadopoulos K, Yap TA, Piha-Paul SA, Lorusso P, Hu-Lieskovan S, Shepherd CJ, Marshall S, Holz J-B, Poon E, Grabowska UB, et al. A first-in-human phase I study of FS120, an OX40/CD137 tetravalent bispecific antibody, in patients with advanced malignancies. Ann Oncol. 2021;32:S864–S865. doi:10.1016/j.annonc.2021.08.1417.
   Web of Science ®Google Scholar
• Lakins MA, Koers A, Giambalvo R, Munoz-Olaya J, Hughes R, Goodman E, Marshall S, Wollerton F, Batey S, Gliddon D, et al. FS222, a CD137/PD-L1 tetravalent bispecific antibody, exhibits low toxicity and antitumor activity in colorectal cancer models. Clinical Cancer Research. 2020;26(4154–4167):4154–67. doi:10.1158/1078-0432.Ccr-19-2958.
   PubMedGoogle Scholar
• Jeong S, Park E, Kim H-D, Sung E, Kim H, Jeon J, Kim Y, Jung U-J, Son Y-G, Hong Y, et al. Novel anti-4-1BBxPD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade. J Immunother Cancer. 2021;9(7):e002428. doi:10.1136/jitc-2021-002428.
   PubMed Web of Science ®Google Scholar
• Lee Y, Lee S, Kim Y, Chung H, Park K, Park E, Park KS, Jung J, Sung B, Won J, et al. A novel anti-CD137 antibody recognizing the membrane-proximal CD137 domain elicits potent anti-tumor T cell activity in a bispecific antibody format. Cancer Res. 2021;81(13_Supplement):1850. doi:10.1158/1538-7445.AM2021-1850 .
   Web of Science ®Google Scholar
• Qiao Y, Qiu Y, Ding J, Luo N, Wang H, Ling X, Sun J, Wu Z, Wang Y, Liu Y, et al. Cancer immune therapy with PD-1-dependent CD137 co-stimulation provides localized tumour killing without systemic toxicity. Nat Commun. 2021;12(6360). doi:10.1038/s41467-021-26645-6
   Google Scholar
• Legg JW. Tumor dependent co-stimulation of CD137/4-1BB in PSMA positive tumors: preclinical characterization of CB307, a half-life extended PSMAxCD137 bispecific Humabody therapeutic. Cancer Res. 2020;80(16_Supplement):3352–3352. doi:10.1158/1538-7445.Am2020-3352.
   Web of Science ®Google Scholar
• Hashimoto K, Pierce AJ, Chau A, Bartlett P, Lloyd P, Maginn M, Machacek M, Vollmer J, Rajbally S, Tilson J, et al. A phase I open-label, dose escalation and expansion trial to investigate the safety, pharmacokinetics and pharmacodynamics of CB307, a trispecific Humabody T-cell enhancer, in patients with PSMA plus advanced and/or metastatic solid tumors (POTENTIA). Cancer Res. 2021;81(13_Supplement):CT206–CT206. doi:10.1158/1538-7445.AM2021-CT206.
   Web of Science ®Google Scholar
• Morales-Kastresana A, Pavlidou M, Peper J, Pattarini L, Barthels C, Hansbauer EM, Bel Aiba R, Bossenmaier B, Scholer-Dahirel A, Jaquin T, et al. Simultaneous costimulatory T-cell engagement and checkpoint inhibition by PRS-344/S095012, a PD-L1/4-1BB bispecific compound for tumor localized activation of the immune system. Cancer Res. 2021;81(13_Supplement):LB135–LB135. doi:10.1158/1538-7445.AM2021-LB135.
   Web of Science ®Google Scholar
• Peper-Gabriel JK, Pavlidou M, Pattarini L, Morales-Kastresana A, Jaquin TJ, Gallou C, Hansbauer E-M, Richter M, Lelievre H, Scholer-Dahirel A, et al. The PD-L1/4-1BB bispecific Antibody-Anticalin fusion protein PRS-344/S095012 elicits strong T-cell stimulation in a tumor-localized manner. Clin Cancer Res. 2022;28(15):3387–99. doi:10.1158/1078-0432.CCR-21-2762.
   PubMed Web of Science ®Google Scholar
• Hui YW, Li T, Ren Y, Hoenemann D, Mei J, Shan B, Hou B. Atg-101, a Novel Pd-L1/4-1bb bispecific antibody, augments anti-tumor immunity through immune checkpoint inhibition and Pdl1-Directed 4-1bb activation. Journal for Immunotherapy of Cancer. 2021;9(Suppl 2):A936–A937. doi:10.1136/jitc-2021-SITC2021.893.
   Google Scholar
• Upadhyaya P, Hurov K, Kublin J, Ma J, Repash E, Kleyman M, Kristensson J, Kanakia D, You F, Chen L, et al. Bt7480, a Fully synthetic tumor-targeted immune cell agonist (Tica (Tm)) induces tumor localized Cd137 agonism and modulation of tumor immune microenvironment. Journal for Immunotherapy of Cancer. 2020;8:A424–A424. doi:10.1136/jitc-2020-SITC2020.0706.
   Web of Science ®Google Scholar
• Hurov K, Lahdenranta J, Upadhyaya P, Haines E, Cohen H, Repash E, Kanakia D, Ma J, Kristensson J, You F, et al. BT7480, a novel fully synthetic bicycle tumor-targeted immune cell agonist™ (Bicycle TICA™) induces tumor localized CD137 agonism. J Immunother Cancer. 2021;9(11):e002883. doi:10.1136/jitc-2021-002883.
   PubMed Web of Science ®Google Scholar
• Upadhyaya P, Lahdenranta J, Hurov K, Battula S, Dods R, Haines E, Kleyman M, Kristensson J, Kublin J, Lani R, et al. Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist. J Immunother Cancer. 2021;9(1):e001762. doi:10.1136/jitc-2020-001762.
   PubMed Web of Science ®Google Scholar
• Hurov K, Lahdenranta J, Upadhyaya P, Kanakia D, Repash E, You F, Ma J, Haines E, Cohen H, McDonnell K, et al. Abstract 1728: nectin-4-dependent immune cell stimulation and anti-tumor efficacy by BT7480, a Nectin-4/CD137 Bicycle ®tumor-targeted immune cell agonist (TICA™). Cancer Res. 2021;81(13_Supplement):1728–1728. doi:10.1158/1538-7445.AM2021-1728.
   Web of Science ®Google Scholar
• Zhai T, Wang C, Xu Y, Huang W, Yuan Z, Wang T, Dai S, Peng S, Pang T, Jiang W, et al. Generation of a safe and efficacious llama single-domain antibody fragment (vHH) targeting the membrane-proximal region of 4-1BB for engineering therapeutic bispecific antibodies for cancer. J Immunother Cancer. 2021;9(6):e002131. doi:10.1136/jitc-2020-002131.
   PubMed Web of Science ®Google Scholar
• Huang X, Sun J, Qin Y, Lin H, Guan J, Lai S, Kang X, Ling H. LBL-024, an anti-PD-L1 and 4-1BB bispecific antibody with highly differentiated binding affinity, shows anti-tumor efficacy in a mouse tumor model. Cancer Res. 2021;81(13_Supplement):1838–1838. doi:10.1158/1538-7445.AM2021-1838.
   Web of Science ®Google Scholar
• Song MY, Lee E-J, Chung H, Lee Y, Park YB, Jee MH, Kim K, Ju M, Lee JK, Choi BH, et al. A novel HER2/4-1BB bispecific antibody, YH32367 (ABL105) shows potent anti-tumor effect through tumor-directed T cell activation. Cancer Res. 2020;80(16_Supplement):6524–6524. doi:10.1158/1538-7445.Am2020-6524.
   Web of Science ®Google Scholar
• Gao Y, Yang T, Liu H, Song N, Dai C, Ding Y. Development and characterization of a novel human CD137 agonistic antibody with anti-tumor activity and a good safety profile in non-human primates. FEBS Open Bio. 2022;12(12):2166–78. doi:10.1002/2211-5463.13494.
   PubMed Web of Science ®Google Scholar
• DiLillo DJ, Ravetch JV. Fc-receptor interactions regulate both cytotoxic and immunomodulatory therapeutic antibody effector functions. Cancer Immunol Res. 2015;3(704–713):704–13. doi:10.1158/2326-6066.CIR-15-0120.
   PubMedGoogle Scholar
• Steiner D, Merz FW, Sonderegger I, Gulotti-Georgieva M, Villemagne D, Phillips DJ, Forrer P, Stumpp MT, Zitt C, Binz HK, et al. Half-life extension using serum albumin-binding DARPin(R) domains. Protein Eng Des Sel. 2017;30(583–591):583–91. doi:10.1093/protein/gzx022.
   PubMedGoogle Scholar
• Hurov K, Upadhyaya P, Lahdenranta J, Kublin J, Ma J, Repash E, Kleyman M, Kristensson J, Chen L, Haines E, et al. BT7480, a novel fully synthetic tumor-targeted immune cell agonist (TICA (TM)) induces tumor localized 4-1BB agonism. Cancer Res. 2020;80(16_Supplement):5552–5552. doi:10.1158/1538-7445.Am2020-5552.
   Web of Science ®Google Scholar
• Stumpp MT, Amstutz P. DARPins: a true alternative to antibodies. Curr Opin Drug Discov Devel. 2007;10(2):153–159.
   PubMedGoogle Scholar
• Rhodes CA, Pei D. Bicyclic peptides as next-generation therapeutics. Chemistry. 2017;23(12690–12703). doi:10.1002/chem.201702117.
   PubMedGoogle Scholar
• Zapata JM, Perez-Chacon G, Carr-Baena P, Martinez-Forero I, Azpilikueta A, Otano I, Melero I. CD137 (4-1BB) Signalosome: complexity Is a Matter of TRAFs. Front Immunol. 2018;9(2618). doi:10.3389/fimmu.2018.02618.
   Google Scholar
• Wyzgol A, Muller N, Fick A, Munkel S, Grigoleit GU, Pfizenmaier K, Wajant H. Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand. J Immunol. 2009;183(1851–1861):1851–61. doi:10.4049/jimmunol.0802597.
   PubMedGoogle Scholar
• Eun SY, Lee SW, Xu Y, Croft M. 4-1BB ligand signaling to T cells limits T cell activation. J Immunol. 2015;194(134–141):134–41. doi:10.4049/jimmunol.1401383.
   PubMedGoogle Scholar
• Macdonald DC, Hotblack A, Akbar S, Britton G, Collins MK, Rosenberg WC. 4-1BB ligand activates bystander dendritic cells to enhance immunization in trans. J Immunol. 2014;193(5056–5064):5056–64. doi:10.4049/jimmunol.1301723.
   PubMedGoogle Scholar
• Fellermeier S, Beha N, Meyer J-E, Ring S, Bader S, Kontermann RE, Müller D. Advancing targeted co-stimulation with antibody-fusion proteins by introducing TNF superfamily members in a single-chain format. Oncoimmunology. 2016;5(e1238540):e1238540. doi:10.1080/2162402X.2016.1238540.
   PubMedGoogle Scholar
• Muik A, Adams HC, Gieseke F, Altintas I, Schoedel KB, Blum JM, Sänger B, Burm SM, Stanganello E, Verzijl D, et al. DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity. J Immunother Cancer. 2022;10(6):e004322. doi:10.1136/jitc-2021-004322.
   PubMed Web of Science ®Google Scholar
• Thurber GM, Dane Wittrup K. A mechanistic compartmental model for total antibody uptake in tumors. J Theor Biol. 2012;314(57–68):57–68. doi:10.1016/j.jtbi.2012.08.034.
   PubMedGoogle Scholar
• Otano I, Azpilikueta A, Glez-Vaz J, Alvarez M, Medina-Echeverz J, Cortés-Domínguez I, Ortiz-de-Solorzano C, Ellmark P, Fritzell S, Hernandez-Hoyos G, et al. CD137 (4-1BB) costimulation of CD8(+) T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation. Nat Commun. 2021;12(7296). doi:10.1038/s41467-021-27613-w
   PubMedGoogle Scholar
• Oh SA, Wu D-C, Cheung J, Navarro A, Xiong H, Cubas R, Totpal K, Chiu H, Wu Y, Comps-Agrar L, et al. PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer. Nat Cancer. 2020;1(681–691):681–91. doi:10.1038/s43018-020-0075-x.
   PubMedGoogle Scholar
• Blackburn SD, Shin H, Freeman GJ, Wherry EJ. Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade. Proc Natl Acad Sci U S A. 2008;105(15016–15021):15016–21. doi:10.1073/pnas.0801497105.
   PubMedGoogle Scholar
• Paley MA, Kroy DC, Odorizzi PM, Johnnidis JB, Dolfi DV, Barnett BE, Bikoff EK, Robertson EJ, Lauer GM, Reiner SL, et al. Progenitor and terminal subsets of CD8+T cells cooperate to contain chronic viral infection. Science. 2012;338(1220–1225):1220–25. doi:10.1126/science.1229620.
   PubMedGoogle Scholar
• Bartkowiak T, Jaiswal AR, Ager CR, Chin R, Chen C-H, Budhani P, Ai M, Reilley MJ, Sebastian MM, Hong DS, et al. Activation of 4-1BB on liver myeloid cells triggers hepatitis via an interleukin-27-dependent pathway. Clin Cancer Res. 2018;24(1138–1151):1138–51. doi:10.1158/1078-0432.CCR-17-1847.
   PubMedGoogle Scholar
• Zhang J, Song K, Wang J, Li Y, Liu S, Dai C, Chen L, Wang S, Qin Z. S100A4 blockage alleviates agonistic anti-CD137 antibody-induced liver pathology without disruption of antitumor immunity. Oncoimmunology. 2018;7(e1296996):e1296996. doi:10.1080/2162402X.2017.1296996.
   PubMedGoogle Scholar
• Kerntke C, Nimmerjahn F, Biburger M. There is (scientific) strength in numbers: a comprehensive quantitation of Fc gamma receptor numbers on human and murine peripheral blood leukocytes. Front Immunol. 2020;11(118). doi:10.3389/fimmu.2020.00118.
   PubMedGoogle Scholar
• Vonderheide RH, Glennie MJ. Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res. 2013;19(1035–1043):1035–43. doi:10.1158/1078-0432.CCR-12-2064.
   PubMedGoogle Scholar
• Buchan SL, Dou L, Remer M, Booth SG, Dunn SN, Lai C, Semmrich M, Teige I, Mårtensson L, Penfold CA, et al. Antibodies to costimulatory receptor 4-1BB enhance anti-tumor immunity via T regulatory cell depletion and promotion of CD8 T cell effector function. Immunity. 2018;49(5):958–970 e957. doi:10.1016/j.immuni.2018.09.014.
   PubMed Web of Science ®Google Scholar
• Derebe MG, Nanjunda RK, Gilliland GL, Lacy ER, Chiu ML. Human IgG subclass cross-species reactivity to mouse and cynomolgus monkey Fcgamma receptors. Immunol Lett. 2018;197(1–8):1–8. doi:10.1016/j.imlet.2018.02.006.
   PubMedGoogle Scholar
• Dekkers G, Bentlage AEH, Stegmann TC, Howie HL, Lissenberg-Thunnissen S, Zimring J, Rispens T, Vidarsson G. Affinity of human IgG subclasses to mouse Fc gamma receptors. MAbs. 2017;9(767–773):767–73. doi:10.1080/19420862.2017.1323159.
   PubMedGoogle Scholar
• Bitra A, Doukov T, Destito G, Croft M, Zajonc DM. Crystal structure of the m4-1BB/4-1BBL complex reveals an unusual dimeric ligand that undergoes structural changes upon 4-1BB receptor binding. J Biol Chem. 2019;294(1831–1845):1831–45. doi:10.1074/jbc.RA118.006297.
   PubMedGoogle Scholar
• Piha-Paul S, Bendell J, Tolcher A, Hurvitz S, Patnaik A, Shroff R, Pohlmann P, Zettl M, Hahn N, Krishnamurthy A, et al. A Phase 1 Dose Escalation Study of Prs-343, a Her2/4-1bb Bispecific Molecule, in patients with her2-positive malignancies. Journal for Immunotherapy of Cancer. 2020;8:A1–A2. doi:10.1136/Lba2019.2.
   Web of Science ®Google Scholar
• Shojaie L, Ali M, Iorga A, Dara L. Mechanisms of immune checkpoint inhibitor-mediated liver injury. Acta Pharm Sin B. 2021;11(3727–3739):3727–39. doi:10.1016/j.apsb.2021.10.003.
   PubMedGoogle Scholar
• Iwai Y, Terawaki S, Ikegawa M, Okazaki T, Honjo T. PD-1 inhibits antiviral immunity at the effector phase in the liver. J Exp Med. 2003;198(39–50):39–50. doi:10.1084/jem.20022235.
   PubMedGoogle Scholar
• Albandar HJ, Fuqua J, Albandar JM, Safi S, Merrill SA, Ma PC. Immune-related adverse events (irAE) in cancer immune checkpoint inhibitors (ICI) and Survival outcomes correlation: to rechallenge or Not? Cancers (Basel). 2021;13(5):989. doi:10.3390/cancers13050989.
   PubMed Web of Science ®Google Scholar
• Zhou X, Yao Z, Yang H, Liang N, Zhang X, Zhang F. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med. 2020;18(87). doi:10.1186/s12916-020-01549-2.
   Google Scholar
• Conroy M, Naidoo J. Immune-related adverse events and the balancing act of immunotherapy. Nat Commun. 2022;13(392). doi:10.1038/s41467-022-27960-2.
   Google Scholar
• Etxeberria I, Glez-Vaz J, Teijeira A, Melero I. New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis. ESMO Open. 2020;4(e000733). doi:10.1136/esmoopen-2020-000733.
   PubMedGoogle Scholar
• Bartkowiak T, Curran MA. 4-1BB agonists: multi-potent potentiators of tumor immunity. Front Oncol. 2015;5(117). doi:10.3389/fonc.2015.00117.
   PubMedGoogle Scholar
• Choi BK, Kim YH, Kwon PM, Lee SC, Kang SW, Kim MS, Lee MJ, Kwon BS. 4-1BB functions as a survival factor in dendritic cells. J Immunol. 2009;182(4107–4115):4107–15. doi:10.4049/jimmunol.0800459.
   PubMedGoogle Scholar
• Stoll A, Bruns H, Fuchs M, Völkl S, Nimmerjahn F, Kunz M, Peipp M, Mackensen A, Mougiakakos D. CD137 (4-1BB) stimulation leads to metabolic and functional reprogramming of human monocytes/macrophages enhancing their tumoricidal activity. Leukemia. 2021;35(3482–3496):3482–96. doi:10.1038/s41375-021-01287-1.
   PubMedGoogle Scholar
• Jiang P, Gao W, Ma T, Wang R, Piao Y, Dong X, Wang P, Zhang X, Liu Y, Su W, et al. CD137 promotes bone metastasis of breast cancer by enhancing the migration and osteoclast differentiation of monocytes/macrophages. Theranostics. 2019;9(2950–2966):2950–66. doi:10.7150/thno.29617.
   PubMedGoogle Scholar
• Wensman H, Kamgari N, Johansson A, Grujic M, Calounova G, Lundequist A, Rönnberg E, Pejler G. Tumor-mast cell interactions: induction of pro-tumorigenic genes and anti-tumorigenic 4-1BB in MCs in response to Lewis lung carcinoma. Mol Immunol. 2012;50(210–219):210–19. doi:10.1016/j.molimm.2012.01.009.
   PubMedGoogle Scholar
• Nishimoto H, Lee S-W, Hong H, Potter KG, Maeda-Yamamoto M, Kinoshita T, Kawakami Y, Mittler RS, Kwon BS, Ware CF, et al. Costimulation of mast cells by 4-1BB, a member of the tumor necrosis factor receptor superfamily, with the high-affinity IgE receptor. Blood. 2005;106(4241–4248):4241–48. doi:10.1182/blood-2005-04-1358.
   PubMedGoogle Scholar
• Heinisch IV, Daigle I, Knopfli B, Simon HU. CD137 activation abrogates granulocyte-macrophage colony-stimulating factor-mediated anti-apoptosis in neutrophils. Eur J Immunol. 2000;30(3441–3446):3441–46. doi:10.1002/1521-4141(2000012)30:12<3441::AID-IMMU3441>3.0.CO;2-L.
   PubMedGoogle Scholar
• Heinisch IV, Bizer C, Volgger W, Simon HU. Functional CD137 receptors are expressed by eosinophils from patients with IgE-mediated allergic responses but not by eosinophils from patients with non-IgE-mediated eosinophilic disorders. J Allergy Clin Immunol. 2001;108(21–28):21–28. doi:10.1067/mai.2001.116864.
   PubMedGoogle Scholar
• Tu TH, Kim C-S, Goto T, Kawada T, Kim B-S, Yu R. 4-1BB/4-1BBL interaction promotes obesity-induced adipose inflammation by triggering bidirectional inflammatory signaling in adipocytes/macrophages. Mediators Inflamm. 2012;2012(972629):1–10. doi:10.1155/2012/972629.
   Google Scholar
• Yuan W, Xu C, Li B, Xia H, Pan Y, Zhong W, Xu L, Chen R, Wang B. Contributions of costimulatory molecule CD137 in endothelial cells. J Am Heart Assoc. 2021;10(e020721). doi:10.1161/JAHA.120.020721.
   Google Scholar
• Palazon A, Teijeira A, Martínez-Forero I, Hervás-Stubbs S, Roncal C, Peñuelas I, Dubrot J, Morales-Kastresana A, Pérez-Gracia JL, Ochoa MC, et al. Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. Cancer Res. 2011;71(801–811):801–11. doi:10.1158/0008-5472.CAN-10-1733.
   PubMedGoogle Scholar
• Foda BM, Ciecko AE, Serreze DV, Ridgway WM, Geurts AM, Chen Y-G. The CD137 ligand is important for Type 1 diabetes development but dispensable for the homeostasis of disease-suppressive CD137(+) FOXP3(+) regulatory CD4 T cells. J Immunol. 2020;204(2887–2899):2887–99. doi:10.4049/jimmunol.1900485.
   PubMedGoogle Scholar
• Forsberg MH, Ciecko AE, Bednar KJ, Itoh A, Kachapati K, Ridgway WM, Chen Y-G. CD137 plays both pathogenic and protective roles in type 1 diabetes development in NOD mice. J Immunol. 2017;198(3857–3868):3857–68. doi:10.4049/jimmunol.1601851.
   PubMedGoogle Scholar
• Le NH, Kim C-S, Tu TH, Choi H-S, Kim B-S, Kawada T, Goto T, Park T, Yoon Park JH, Yu R, et al. Blockade of 4-1BB and 4-1BBL interaction reduces obesity-induced skeletal muscle inflammation. Mediators Inflamm. 2013;2013(865159):1–10. doi:10.1155/2013/865159.
   Google Scholar
• Mayes PA, Hance KW, Hoos A. The promise and challenges of immune agonist antibody development in cancer. Nat Rev Drug Discov. 2018;17(509–527):509–27. doi:10.1038/nrd.2018.75.
   PubMedGoogle Scholar
• Betts A, van der Graaf PH. Mechanistic quantitative pharmacology strategies for the early clinical development of bispecific antibodies in oncology. Clin Pharmacol Ther. 2020;108(528–541):528–41. doi:10.1002/cpt.1961.
   PubMedGoogle Scholar
• Laderach D, Movassagh M, Johnson A, Mittler RS, Galy A. 4-1BB co-stimulation enhances human CD8(+) T cell priming by augmenting the proliferation and survival of effector CD8(+) T cells. Int Immunol. 2002;14(1155–1167):1155–67. doi:10.1093/intimm/dxf080.
   PubMedGoogle Scholar
• Martinez-Forero I, Azpilikueta A, Bolaños-Mateo E, Nistal-Villan E, Palazon A, Teijeira A, Perez-Chacon G, Morales-Kastresana A, Murillo O, Jure-Kunkel M, et al. T cell costimulation with anti-CD137 monoclonal antibodies is mediated by K63-polyubiquitin-dependent signals from endosomes. J Immunol. 2013;190(6694–6706):6694–706. doi:10.4049/jimmunol.1203010.
   PubMedGoogle Scholar
• Glez-Vaz J, Azpilikueta A, Olivera I, Cirella A, Teijeira A, Ochoa MC, Alvarez M, Eguren-Santamaria I, Luri-Rey C, Rodriguez-Ruiz ME, et al. Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies. J Immunother Cancer. 2022;10(3):e003532. doi:10.1136/jitc-2021-003532.
   PubMed Web of Science ®Google Scholar
• Seidel J, Leitzke S, Ahrens B, Sperrhacke M, Bhakdi S, Reiss K. Role of ADAM10 and ADAM17 in regulating CD137 Function. Int J Mol Sci. 2021;22(5):2730. doi:10.3390/ijms22052730.
   PubMed Web of Science ®Google Scholar
• Ye Q, Song DG, Poussin M, Yamamoto T, Best A, Li C, Coukos G, Powell DJ Jr. CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin Cancer Res. 2014;20(44–55):44–55. doi:10.1158/1078-0432.CCR-13-0945.
   PubMedGoogle Scholar
• Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, Wunderlich JR, Mixon A, Farid S, Dudley ME, et al. PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors. J Clin Invest. 2014;124(2246–2259):2246–59. doi:10.1172/JCI73639.
   PubMedGoogle Scholar
• Kim HD, Park S, Jeong S, Lee YJ, Lee H, Kim CG, Kim KH, Hong SM, Lee JY, Kim S, et al. 4-1BB delinates distinct activation status of exhausted tumor-infiltrating CD8(+) T cells in hepatocellular carcinoma. Hepatology. 2020;71(3): 955–971. doi:10.1002/hep.30881.
   PubMed Web of Science ®Google Scholar
• Zheng L, Qin S, Si W, Wang A, Xing B, Gao R, Ren X, Wang L, Wu X, Zhang J, et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells. Science. 2021;374(abe6474). doi:10.1126/science.abe6474
   Google Scholar
• Datar I, Sanmamed MF, Wang J, Henick BS, Choi J, Badri T, Dong W, Mani N, Toki M, Meijas LD, et al. Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non-small cell lung cancer using spatially resolved and multiparametric single-cell analysis. Clin Cancer Res. 2019;25(4663–4673):4663–73. doi:10.1158/1078-0432.CCR-18-4142.
   PubMedGoogle Scholar
• Eiva MA, Omran DK, Chacon JA, Powell DJ Jr. Systematic analysis of CD39, CD103, CD137, and PD-1 as biomarkers for naturally occurring tumor antigen-specific TILs. Eur J Immunol. 2022;52(1):96–108. doi:10.1002/eji.202149329.
   PubMed Web of Science ®Google Scholar
• Leem G, Park J, Jeon M, Kim ES, Kim SW, Lee YJ, Choi SJ, Choi B, Park S, Ju YS, et al. 4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39+CD8 T cells from primary and metastatic sites of epithelial ovarian cancers. J Immunother Cancer. 2020;8(2):e001650. doi:10.1136/jitc-2020-001650.
   PubMed Web of Science ®Google Scholar
• Duhen T, Duhen R, Montler R, Moses J, Moudgil T, de Miranda NF, Goodall CP, Blair TC, Fox BA, McDermott JE, et al. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nat Commun. 2018;9(2724). doi:10.1038/s41467-018-05072-0
   PubMedGoogle Scholar
• Ugolini A, Nuti M. CD137(+) T-cells: protagonists of the immunotherapy revolution. Cancers (Basel). 2021;13(3):456. doi:10.3390/cancers13030456.
   PubMed Web of Science ®Google Scholar
• Ovacik M, Lin K. Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development. Clin Transl Sci. 2018;11(540–552):540–52. doi:10.1111/cts.12567.
   PubMedGoogle Scholar
• Novakovic AM, Wilkins JJ, Dai H, Wade JR, Neuteboom B, Brar S, Bello CL, Girard P, Khandelwal A. Changing body weight-based dosing to a flat dose for avelumab in metastatic Merkel cell and advanced urothelial carcinoma. Clin Pharmacol Ther. 2020;107(588–596):588–96. doi:10.1002/cpt.1645.
   PubMedGoogle Scholar
• Giffin MJ, Cooke K, Lobenhofer EK, Estrada J, Zhan J, Deegen P, Thomas M, Murawsky CM, Werner J, Liu S, et al. AMG 757, a half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer. Clin Cancer Res. 2021;27(1526–1537):1526–37. doi:10.1158/1078-0432.CCR-20-2845.
   PubMedGoogle Scholar
• Houot R, Kohrt H, Levy R. Boosting antibody-dependent cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody. Oncoimmunology. 2012;1(957–958):957–58. doi:10.4161/onci.19974.
   PubMedGoogle Scholar
• Opzoomer JW, Sosnowska D, Anstee JE, Spicer JF, Arnold JN. Cytotoxic chemotherapy as an immune stimulus: a molecular perspective on turning up the immunological heat on cancer. Front Immunol. 2019;10(1654). doi:10.3389/fimmu.2019.01654.
   PubMedGoogle Scholar
• Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst. 2013;105(256–265):256–65. doi:10.1093/jnci/djs629.
   PubMedGoogle Scholar
• Barsoumian HB, Ramapriyan R, Younes AI, Caetano MS, Menon H, Comeaux NI, Cushman TR, Schoenhals JE, Cadena AP, Reilly TP, et al. Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma. J Immunother Cancer. 2020;8(2):e000537. doi:10.1136/jitc-2020-000537.
   PubMed Web of Science ®Google Scholar
• Benaduce AP, Brenneman R, Schrand B, Pollack A, Gilboa E, Ishkanian A. 4-1BB aptamer-based immunomodulation enhances the therapeutic index of radiation therapy in murine tumor models. Int J Radiat Oncol Biol Phys. 2016;96(458–461):458–61. doi:10.1016/j.ijrobp.2016.05.013.
   PubMedGoogle Scholar
• Qu QX, Zhu X-Y, Du -W-W, Wang H-B, Shen Y, Zhu Y-B, Chen C. 4-1BB agonism combined with PD-L1 blockade increases the number of tissue-resident CD8+ T cells and facilitates tumor abrogation. Front Immunol. 2020;11(577). doi:10.3389/fimmu.2020.00577.
   Google Scholar
• Marofi F, Achmad H, Bokov D, Abdelbasset WK, Alsadoon Z, Chupradit S, Suksatan W, Shariatzadeh S, Hasanpoor Z, Yazdanifar M, et al. Hurdles to breakthrough in CAR T cell therapy of solid tumors. Stem Cell Res Ther. 2022;13(140). doi:10.1186/s13287-022-02819-x
   Google Scholar
• Simoni Y, Becht E, Fehlings M, Loh CY, Koo S-L, Teng KWW, Yeong JPS, Nahar R, Zhang T, Kared H, et al. Bystander CD8(+) T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature. 2018;557(575–579):575–79. doi:10.1038/s41586-018-0130-2.
   PubMedGoogle Scholar